Bupropion for the Treatment of Methamphetamine Dependence - 1

This study has been completed.
Sponsor:
Information provided by:
National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:
NCT00069251
First received: September 18, 2003
Last updated: July 21, 2008
Last verified: July 2008
  Purpose

The purpose of this study is to assess the efficacy and safety of bupropion in reducing methamphetamine use in subjects with methamphetamine dependence


Condition Intervention Phase
Amphetamine-Related Disorders
Drug: Bupropion
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Bupropion for the Treatment of Methamphetamine Dependence

Resource links provided by NLM:


Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Severity addiction
  • Methamphetamine use

Estimated Enrollment: 150
Study Start Date: July 2003
Estimated Study Completion Date: June 2005
Detailed Description:

A double-blind, placebo-controlled, parallel-group design study in which 100 subjects will be randomly assigned to placebo or bupropion for 12 weeks with follow-up assessments 4 weeks following treatment. Adaptive randomization will be used to balance treatment groups based on gender.

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subject must have methamphetamine dependence as determined by the DSM-IV diagnosis
  • Subject must be willing to comply with study procedures.
  • Ability to verbalize understanding of consent form, provide written consent, and verbalize willingness to complete study procedures
  • Be able to comply with protocol requirements

Exclusion Criteria:

  • Please contact site for more information.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00069251

Locations
United States, California
Matrix Institute on Addictions
Costa Mesa, California, United States, 92627
South Bay Treatment Center
San Diego, California, United States, 92105
United States, Hawaii
Pacific Addiction Research Center
Honolulu, Hawaii, United States, 96813
United States, Iowa
Powell Chemical Dependency Center
Des Moines, Iowa, United States, 50316
United States, Missouri
University of Missouri - Kansas City
Kansas City, Missouri, United States, 64108
Sponsors and Collaborators
Investigators
Principal Investigator: Richard Rawson, Ph.D. University of California, Los Angeles
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00069251     History of Changes
Other Study ID Numbers: NIDA-CTO-0008-1
Study First Received: September 18, 2003
Last Updated: July 21, 2008
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Amphetamine-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Methamphetamine
Bupropion
Central Nervous System Stimulants
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Sympathomimetics
Autonomic Agents
Peripheral Nervous System Agents
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Adrenergic Agents
Adrenergic Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Dopamine Uptake Inhibitors
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs

ClinicalTrials.gov processed this record on September 11, 2014